- Report
- February 2024
- 70 Pages
Japan
From €4550EUR$4,750USD£3,874GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4550EUR$4,750USD£3,874GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4550EUR$4,750USD£3,874GBP
- Report
- April 2023
- 110 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- October 2022
- 70 Pages
Africa
From €4550EUR$4,750USD£3,874GBP
- Report
- August 2020
- 150 Pages
Global
From €4071EUR$4,250USD£3,466GBP
- Report
- October 2019
- 125 Pages
Canada
From €4550EUR$4,750USD£3,874GBP
- Report
- October 2022
- 138 Pages
Global
From €4262EUR$4,450USD£3,630GBP
- Report
- May 2020
- 121 Pages
Global
From €4166EUR$4,350USD£3,548GBP
- Report
- April 2020
- 119 Pages
Global
From €3506EUR$3,660USD£2,985GBP
- Report
- January 2021
- 149 Pages
China, Global
From €3000EUR$3,355USD£2,644GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$3,915USD£3,085GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$3,915USD£3,085GBP
- Report
- May 2024
- 50 Pages
Global
From €2538EUR$2,650USD£2,161GBP
Linagliptin is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas. Linagliptin is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Linagliptin is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to control blood sugar levels, reduce cholesterol, and regulate hormones.
Companies in the Linagliptin market include Boehringer Ingelheim, Merck, Novartis, and Eli Lilly. Show Less Read more